Is compounded tirzepatide still allowed in 2026?

Only in limited, compliant situations. Once tirzepatide injection shortages were declared resolved, shortage-based mass compounding is not broadly allowed, and compounding must revert to standard 503A/503B restrictions with patient-specific medical necessity and clinician oversight.

Did the FDA ban compounded semaglutide or tirzepatide?

The FDA did not ban all compounding. Instead, it ended broad enforcement discretion that was tied to national shortages. Compounding may still be legal in narrow circumstances, but it is no longer widely permitted as a routine alternative to FDA-approved products.

What does "FDA enforcement discretion" mean for GLP-1 compounding?

Enforcement discretion is a temporary period when the FDA may choose not to enforce certain restrictions during exceptional circumstances such as drug shortages. Once a shortage is resolved, compounding generally must return to standard legal limits.

Are compounded semaglutide and tirzepatide FDA-approved?

No. Compounded semaglutide and tirzepatide are not FDA-approved medications. They may be legally compounded only under specific conditions by appropriately regulated U.S. pharmacies and used under clinician supervision when medically necessary.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

503A pharmacies compound patient-specific prescriptions and are primarily overseen by state boards of pharmacy. 503B outsourcing facilities are FDA-registered and can compound sterile medications in larger batches under FDA oversight and inspection. Both still have limits, especially after shortages are resolved.

How can I tell if compounded semaglutide or tirzepatide is legitimate?

Legitimate compounded GLP-1 medication should come from a U.S.-licensed pharmacy (or FDA-registered outsourcing facility), require a prescription, include a lot number and beyond-use date (BUD), and be dispensed with clinician oversight. Transparency about sourcing and quality testing is essential.

What red flags suggest a compounded GLP-1 product may be unsafe or counterfeit?

Major red flags include ultra-low pricing, no physical address or phone number, "research chemical" or "not for human use" labeling, products promoted as semaglutide/tirzepatide salts, DIY powder-and-diluent kits, no batch documentation (such as a COA), missing lot number or BUD, or no prescription requirement.

What is a Certificate of Analysis (COA), and should I ask about it?

A Certificate of Analysis (COA) is documentation associated with testing that helps verify identity and purity (and sometimes potency) of ingredients or batches. Patients may not always receive full lab documents directly, but reputable clinics and pharmacies should be transparent about quality controls and traceability.

What is a Beyond-Use Date (BUD), and why does it matter for compounded injections?

A beyond-use date (BUD) is the date after which a compounded medication should not be used. It is different from an FDA-manufactured expiration date. Legitimate compounded vials should show a BUD and a lot number for traceability and safety.

Is "semaglutide sodium" (or other semaglutide salts) the same as semaglutide?

Patients should be cautious. Products marketed as semaglutide or tirzepatide "salts" or labeled for research use are a common warning sign of non-compliant sourcing. Ask your clinician to verify the pharmacy, formulation, and documentation before using any product.

Are online "research peptide" semaglutide or tirzepatide products safe?

No. Products sold as "research chemicals" or "not for human use" are not intended for injection in people and often bypass medical oversight, sterility standards, and reliable quality testing.

What is the FDA "Green List" and Import Alert 66-80?

The FDA uses Import Alert 66-80 and related resources (often discussed as a "Green List" context) to identify and take action against illegal or non-compliant imported drug ingredients. Clinics and pharmacies should be able to explain how they verify legitimate sourcing and compliance for injectable compounded medications.

If compounded GLP-1 options are limited, what are safer alternatives?

Safer alternatives often include FDA-approved medications dispensed through licensed pharmacies, insurance navigation and prior authorization support, and clinician-guided dosing strategies that prioritize tolerability and adherence. If compounding is used, it should be medically necessary and fully compliant.

What should I do if I already bought compounded semaglutide or tirzepatide online?

Do not inject anything you cannot verify as legitimate and sterile. Contact a licensed clinician and the dispensing pharmacy to confirm licensing, documentation, lot number, and beyond-use date. If the product is labeled for research use, lacks traceability, or seems suspicious, stop and seek medical guidance.

Compounded Semaglutide & Tirzepatide in 2026: FDA Rules, Safety Risks, and How to Choose a Legitimate Pharmacy

Q: Is compounded semaglutide legal in 2026?

Sometimes, but only in limited circumstances. After the FDA declared the semaglutide injection shortage resolved, routine "copycat" compounding is not broadly permitted. Any compounding must follow federal and state rules (503A/503B), be patient-specific, and be prescribed with medical oversight.

Joshua Silva, MD
Oct 3, 2025
5 min read

Updated: Jan 21

Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD

As of 2026, compounded semaglutide and tirzepatide are no longer broadly permitted in the United States.

Following resolution of nationwide shortages, the FDA ended its temporary enforcement discretion, meaning these medications may now only be compounded under limited, legally defined circumstances.¹–³

On February 21, 2025, the U.S. Food and Drug Administration formally declared the semaglutide injection shortage resolved.¹ In the months that followed, the FDA also confirmed the resolution of tirzepatide injection shortages and clarified post-shortage compounding expectations.²,³

Despite this, online advertisements continue to promote “compounded” GLP-1 medications. Some are legally produced and medically appropriate — others are unsafe, non-compliant, or counterfeit.

This guide explains what patients need to know in 2026 to stay safe.

What Are Compounded Medications?

Compounded medications are custom prescriptions prepared by licensed pharmacies to meet an individual patient’s medical needs when FDA-approved products cannot.

Compounding may be appropriate when⁴–⁶:

A required dose, concentration, or formulation is not commercially available
An FDA-approved drug is in a temporary shortage
A patient has a documented allergy or intolerance to an inactive ingredient

Compounding is intended to address medical necessity, not convenience, mass substitution, or price alone.

Are Compounded Semaglutide or Tirzepatide FDA-Approved in 2026?

No. Compounded semaglutide and tirzepatide are not FDA-approved medications.⁴,⁵

However, they may be legally compounded when all of the following are met:

Prepared by U.S.-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities
Used for patient-specific medical needs
Produced in compliance with USP sterile compounding standards
Prescribed and monitored by a licensed clinician

This distinction — not FDA-approved but still FDA-compliant — is critical.

Why Did the FDA End Broad Compounding of Semaglutide and Tirzepatide?

During shortages of Wegovy®, Ozempic®, Mounjaro®, and Zepbound®, the FDA exercised temporary enforcement discretion, allowing compounding pharmacies to help meet patient demand.¹–³

Once manufacturing stabilized:

Semaglutide injection products were removed from the FDA Drug Shortage List¹
Tirzepatide injection products were formally declared resolved²
Compounding reverted to pre-shortage federal and state limits³–⁶

Broad, shortage-based compounding is no longer allowed in 2026.

Safe Compounding vs High-Risk GLP-1 Sources

Infographic titled "Compounded GLP-1 Medications in 2026: FDA Update & Patient Safety Guide" comparing legitimate vs. unsafe sources. The left side ("Safe & Compliant") illustrates requirements for compounded semaglutide and tirzepatide, including U.S.-licensed 503A/503B pharmacies, sterile USP compliance, and clinician oversight. The right side ("High-Risk & Non-Compliant") depicts red flags such as "research chemicals," DIY powder kits, unverified online advertisements, and counterfeit vials lacking certificates of analysis following the FDA shortage resolution.

Legitimate compounded GLP-1 medications:

Use pharmaceutical-grade active pharmaceutical ingredients (APIs)
Are sterile, potency-tested, and traceable
Require a prescription and clinician oversight

High-risk red flags include⁷–¹¹:

Prices far below typical market cost
No physical address or phone number
“Research chemical” or “not for human use” labeling
Semaglutide or tirzepatide promoted as salts
DIY powder-and-diluent kits
No Certificate of Analysis (COA)
Missing lot number or Beyond-Use Date (BUD)
No prescription requirement

How to Safely Choose Compounded Semaglutide or Tirzepatide (When Medically Necessary)

When compounding is appropriate, patients should verify⁴–⁶,⁸–¹²:

U.S.-licensed pharmacy or FDA-registered outsourcing facility
API sourcing compliant with Import Alert 66-80 (“Green List”)
Certificate of Analysis (COA) verifying identity and purity
Sterile, ready-to-inject medication
Lot number and Beyond-Use Date (BUD)
Transparent pricing consistent with pharmaceutical-grade sourcing
Physician oversight and follow-up care

Frequently Asked Questions

Is compounded semaglutide legal in 2026?

Sometimes. After the shortage ended, routine “copycat” compounding is no longer broadly permitted. Compounding must meet strict 503A/503B and patient-specific requirements.¹–³

Did the FDA ban compounded semaglutide?

No. The FDA ended broad enforcement discretion tied to shortages. Compounding is now limited to legally compliant circumstances.¹,³

Is compounded tirzepatide still allowed?

Only in limited, compliant situations. Tirzepatide injection shortages have been formally resolved, and mass compounding is not permitted.²,³

What is FDA enforcement discretion?

It is a temporary policy where the FDA may defer enforcement during exceptional circumstances such as shortages. Once resolved, standard compounding laws apply.³–⁶

What is the difference between a 503A and 503B pharmacy?

503A pharmacies compound patient-specific prescriptions under state oversight
503B outsourcing facilities compound sterile medications under FDA registration and inspectionBoth are subject to limits once shortages end.⁵,⁶,¹²

Is “semaglutide sodium” the same as semaglutide?

Patients should be cautious. FDA communications emphasize concerns with unapproved GLP-1 products and unclear formulations. Products marketed as salts or research chemicals are a major red flag.⁷–¹¹

Are “research peptide” GLP-1 products safe?

No. Products labeled for research use are not intended for human administration and may pose serious safety risks.⁷–¹¹

Why are counterfeit GLP-1 products a concern?

High demand has led to counterfeit Ozempic® entering the U.S. supply chain, prompting FDA consumer warnings.¹⁰

Disclaimer

This article is for educational purposes only and is not a substitute for medical advice.

About the Author

Dr. Joshua Silva, MD, is a licensed physician and Medical Director of Potere Health MD. He earned his medical degree from the University of Hawaiʻi John A. Burns School of Medicine and completed residency training in Occupational and Environmental Medicine at the University of Utah, where he also earned a master’s degree in Occupational Health. He later completed a Master of Business Administration with an emphasis in health care administration at Ohio University.

Dr. Silva specializes in evidence-based weight management, including GLP-1 and GIP therapies such as semaglutide and tirzepatide. He provides in-person and virtual care for patients in Salt Lake City, St. George, and Cedar City, Utah.

References

U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Semaglutide Injection Products (Ozempic and Wegovy). February 21, 2025. Accessed January 21, 2026. https://www.fda.gov/media/185526/download
U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide Injection Products (Mounjaro and Zepbound). December 19, 2024. Accessed January 21, 2026. https://www.fda.gov/media/184606/download
U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. February 21, 2025. Accessed January 21, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. September 16, 2025. Accessed January 21, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
U.S. Food and Drug Administration. Human Drug Compounding. May 15, 2025. Accessed January 21, 2026. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
U.S. Food and Drug Administration. 503A Pharmacies and 503B Outsourcing Facilities. Accessed January 21, 2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. September 25, 2025. Accessed January 21, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
U.S. Food and Drug Administration. FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients. September 5, 2025. Accessed January 21, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-green-list-protect-americans-illegal-imported-glp-1-drug-ingredients
U.S. Food and Drug Administration. Import Alert 66-80. Accessed January 21, 2026. https://www.accessdata.fda.gov/cms_ia/importalert_1186.html
U.S. Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain. December 5, 2025. Accessed January 21, 2026. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain
U.S. Food and Drug Administration. GLP-1 Solution – 09/09/2025 (Warning Letter). September 9, 2025. Accessed January 21, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-09092025
U.S. Food and Drug Administration. Registered Outsourcing Facilities. Updated January 13, 2026. Accessed January 21, 2026. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities